

MITOMYCIN FOR INJECTION

There is only one Canadian supplier of mitomycin for injection¹ (see below). Although listed in the Drug Product Database, Hospira is not currently marketing its brand of mitomycin in Canada.²

DIN	Company	Product	Active Ingredient	Strength
02230450	TEVA CANADA LIMITED	MITOMYCIN FOR INJECTION	MITOMYCIN	5 MG / VIAL
02230451	TEVA CANADA LIMITED	MITOMYCIN FOR INJECTION	MITOMYCIN	20 MG / VIAL

Labelled Indications^{3,4}:

Adjunct palliative treatment for adenocarcinoma of stomach and colon
Topical therapy for superficial carcinoma of the urinary bladder

Off-label Indications^{3,5}:

Treatment of various cancers
Prevention of scarring in glaucoma surgery; prevention of corneal haze after refractive surgery
Topical treatment of tracheal stenosis

Shortage management:

Extemporaneous preparation: High risk product due to cytotoxicity.³

- 0.5 mg/ml solutions prepared with Sterile Water for Injection are stable for 1 week at room temperature and 2 weeks refrigerated. Protect from light.³
- When diluted to 20 to 40 mcg/ml, stable for 3 hours in D5W and 12 hours in Normal Saline at room temperature.³
- As long as bulk chemical remains available, compounding pharmacies can prepare the injectable formulation.⁶

Therapeutic Alternatives:

Indication	Alternative	Comments
Cancer treatment	No single agent can be substituted for mitomycin ⁵ If considering use of mitomycin in combination, ensure adequate supply of mitomycin on hand to complete treatment before starting; if not, select alternative protocol. ⁵	Choice of alternative must be patient-specific and based on renal function, liver function, and the neoplasm type and location. ⁵
Glaucoma surgery (trabeculectomy)	5-fluorouracil ⁷ Bevacizumab ⁸	Evaluate need for antifibrotic agent; reserve use for high risk patients ⁹

Refractive surgery	Ophthalmic corticosteroids e.g. fluorometholone ¹⁰	Reserve mitomycin for high risk patients – severe myopia, deeper ablation ¹⁰
Tracheal stenosis	Benefit of mitomycin for this indication is questionable ^{12,13}	

Prepared by Karen Jensen MSC, BSP; Reviewed by Carmen Bell BSP, Medication Information Consultant; Suzanne Gulka BSP, Clinical Support Pharmacist, RQHR; Janis Johnson BSP, ACPR, Regional Pharmaceutical Consultant, DPEEB.
medSask, December, 2014

References:

1. Drug Product Database. Health Canada website. Available at <http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp>. Accessed 04Dec2014.
2. Hospira Product Catalogue. Available at <http://www.hospira.ca/english/ProductCatalog.aspx>. Accessed 04Dec2014.
3. Mitomycin monograph. In: The Ottawa Hospital Parenteral Drug Therapy Manual, 33rd edition, 2012.
4. Mitomycin for Injection monograph. In Drug Product Database. Health Canada website. Available at <http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=49400&lang=eng>
5. Mitomycin injection. In ASHP Drug Shortages database. Available at <http://www.ashp.org/menu/DrugShortages/CurrentShortages/bulletin.aspx?id=433#sthash.91oMipz6.dpuf> . Accessed 04Dec 2014.
6. Personal communication. Medical Arts Pharmacy, Saskatoon. Dec 9, 2014.
7. Lin Z, Li Y et al. Intraoperative mitomycin C versus intraoperative 5-fluorouracil for trabeculectomy: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2012 Apr;28(2):166-73.
8. Nilforushan N, Yadgari M et al. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012 Feb;153(2):352-357.e1. doi: 10.1016/j.ajo.2011.08.005. Epub 2011 Oct 7.
9. Karmel M. Rethinking mitomycin C. Available at <http://www.aao.org/publications/eyenet/200503/feature.cfm>. Accessed 04Dec2014.
10. Bower K. Laser Refractive Surgery. In UptoDate online. Available at www.uptodate.com by subscription. Accessed 4Dec2014.
11. Hofmeister E, Bishop F, et al. Randomized dose-response analysis of mitomycin-C to prevent haze after photorefractive keratectomy for high myopia. J Cataract Refract Surg 2013; 39:1358–1365.
12. Vorasubin N, Vira D et al. Airway management and endoscopic treatment of subglottic and tracheal stenosis: the laryngeal mask airway technique. Ann Otol Rhinol Laryngol. 2014 Apr;123(4):293-8.
13. Study of Mitomycin-C Application in Laryngotracheal Stenosis. In Clinicaltrials.gov, NIH. Available at <http://clinicaltrials.gov/ct2/show/NCT01523275> . Accessed 04Dec2014.